Roundview Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Roundview Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-368	Closed	-$232K	–	307
2021 Q4	$232K	Buy	368 +35	+11%	+$21.5K	0.02%	280
2021 Q3	$202K	Buy	+333	New	+$207K	0.02%	283
2017 Q3	–	Sell	-852	Closed	-$418K	–	232
2017 Q2	$418K	Buy	+852	New	+$373K	0.12%	161

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Roundview Capital's REGN Position: Q1 2022 in Review

Roundview Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 368 shares — an estimated $232K sold.

Roundview Capital first reported a position in REGN in Q2 2017 and held it in 3 quarters. The position peaked at $418K in Q2 2017. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Roundview Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Roundview Capital sold 368 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $232K.
Roundview Capital first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 3 quarters.
Roundview Capital's Regeneron Pharmaceuticals position peaked at $418K in Q2 2017.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Roundview Capital's 13F filing for Q1 2022, filed 11 May 2022.